Literature DB >> 23357658

What does the HAMD mean?

Stefan Leucht1, Hein Fennema, Rolf Engel, Marion Kaspers-Janssen, Peter Lepping, Armin Szegedi.   

Abstract

Little is known about the clinical relevance of the Hamilton Rating Scale for Depression (HAMD-17) total scores. It is unclear how total scores translate into clinical severity, or what commonly used measures for response (reduction from baseline of ≥ 50% in the total score) and remission (total HAMD-17 score ≤ 7) mean from a clinical perspective. We therefore compared: (a) the percentage and absolute change in the HAMD-17 total scores with Clinical Global Impression-Improvement (CGI-I); (b) the absolute and percentage change in the HAMD-17 total scores with Clinical Global Impression-Severity (CGI-S) absolute change; and (c) the percentage and absolute change in the HAMD-17 total scores with CGI-I in the subgroups of patients with ≤ median and > median HAMD-17 total scores at baseline. The method used was equipercentile linking of HAMD-17 and CGI ratings from 43 drug trials in patients with Major Depressive Disorder (MDD) (n = 7131). Our results confirm the validity of the commonly used measures for remission and response in MDD trials: a CGI-I score of 2 ('much improved') corresponded to a reduction from baseline of > 50% and < 60%, and a CGI-I score of 1 ('very much improved') to a reduction of > 75% and < 85%. The CGI-S score of 1 ('normal., not at all ill') corresponded to the HAMD-17 total score of < 5 and the CGI-S score of 2 ('borderline mentally ill') to the score between 6 and 8. An effect of baseline illness severity was observed.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23357658     DOI: 10.1016/j.jad.2012.12.001

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  52 in total

1.  Possibly no baseline severity effect for antidepressants versus placebo but for antipsychotics. Why?

Authors:  Stefan Leucht; S Z Levine; M Samara; A Cipriani; J M Davis; T A Furukawa
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-10       Impact factor: 5.270

2.  The clinical significance of drug-placebo differences.

Authors:  I Kirsch
Journal:  Epidemiol Psychiatr Sci       Date:  2017-11-23       Impact factor: 6.892

3.  Heterogeneity of postpartum depression: a latent class analysis.

Authors: 
Journal:  Lancet Psychiatry       Date:  2015-01-08       Impact factor: 27.083

Review 4.  Cognitive behavioural therapy halves the risk of repeated suicide attempts: systematic review.

Authors:  Peter C Gøtzsche; Pernille K Gøtzsche
Journal:  J R Soc Med       Date:  2017-10       Impact factor: 5.344

5.  The efficacy of psychotherapies and pharmacotherapies for mental disorders in adults: an umbrella review and meta-analytic evaluation of recent meta-analyses.

Authors:  Falk Leichsenring; Christiane Steinert; Sven Rabung; John P A Ioannidis
Journal:  World Psychiatry       Date:  2022-02       Impact factor: 49.548

6.  Validation of the 17-item Hamilton Depression Rating Scale definition of response for adults with major depressive disorder using equipercentile linking to Clinical Global Impression scale ratings: analysis of Pharmacogenomic Research Network Antidepressant Medication Pharmacogenomic Study (PGRN-AMPS) data.

Authors:  William V Bobo; Gabriela C Angleró; Gregory Jenkins; Daniel K Hall-Flavin; Richard Weinshilboum; Joanna M Biernacka
Journal:  Hum Psychopharmacol       Date:  2016-03-21       Impact factor: 1.672

7.  Improvements in depression and changes in quality of life among HIV-infected adults.

Authors:  Angela M Bengtson; Brian W Pence; Julie O'Donnell; Nathan Thielman; Amy Heine; Anne Zinski; Riddhi Modi; Teena McGuinness; Bradley Gaynes
Journal:  AIDS Care       Date:  2014-08-08

8.  Improvements in Depression and Changes in Fatigue: Results from the SLAM DUNC Depression Treatment Trial.

Authors:  Julie Barroso; Angela M Bengtson; Bradley N Gaynes; Teena McGuinness; Evelyn B Quinlivan; Michelle Ogle; Amy Heine; Nathan M Thielman; Brian W Pence
Journal:  AIDS Behav       Date:  2016-02

Review 9.  Vortioxetine for depression in adults.

Authors:  Markus Koesters; Giovanni Ostuzzi; Giuseppe Guaiana; Johanna Breilmann; Corrado Barbui
Journal:  Cochrane Database Syst Rev       Date:  2017-07-05

10.  Establishing the cut-off score for remission and severity-ranges on the Psychotic Depression Assessment Scale (PDAS).

Authors:  Søren D Østergaard; Anthony J Rothschild; Alastair J Flint; Benoit H Mulsant; Ellen M Whyte; Tom Vermeulen; Per Bech; Barnett S Meyers
Journal:  J Affect Disord       Date:  2015-10-22       Impact factor: 4.839

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.